A year of specific answers
Cannabis research in 2024 produced a mixture of clinical progress, disappointing results and better measurement tools. The useful advances concerned defined products and questions: chemotherapy-related vomiting, insomnia, short-term anxiety ratings, chronic pain and laboratory accuracy. These are five different contributions, rather than evidence that cannabis became a universal treatment.
1. Better control of chemotherapy-related vomiting
A randomized phaseII/III trial published in 2024 tested an oral THC:CBD extract alongside standard care in patients with inadequately controlled chemotherapy-induced nausea and vomiting. Complete response—no vomiting and no rescue medication—was 24% with the extract versus 8% with placebo.
The absolute difference was 16 percentage points. This is a clinically specific result for an additional treatment in a selected population, with adverse effects also part of the assessment. It concerns managing treatment-related symptoms, not treating the cancer itself.
2. CBD did not broadly solve insomnia
A randomized pilot trial compared CBD with placebo in 30 adults with moderate-to-severe insomnia. Most sleep outcomes were similar between groups, although some measures of well-being differed.
The result matters because a substance can improve how participants describe feeling without clearly improving the main sleep measures. The small study leaves room for further research, but it does not establish a broadly effective insomnia medicine.
3. CBG reached an early human test
A double-blind crossover field trial involved 34 healthy adults with prior cannabis experience. It reported reductions in subjective anxiety and stress after CBG compared with placebo.
The contribution was an early controlled human signal for a less-studied cannabinoid. Healthy participants, short-term effects and self-reported ratings make this a different question from long-term treatment of an anxiety disorder. It supplies a reason for further trials, rather than a clinical treatment rule.
4. Chronic-pain benefits remained modest
AHRQ’s 2024 review update found small short-term improvements in pain for some THC-containing products, alongside increased adverse effects such as dizziness and sedation. Products and cannabinoid ratios differed, and much of the evidence concerned neuropathic pain.
The review’s value was synthesis: it put individual positive results beside the wider evidence. A small average benefit may matter to some patients, but it must be considered with tolerability and the particular condition studied.
5. Laboratories gained a common comparison material
In 2024 NIST released a hemp plant reference material to help laboratories measure cannabis constituents more accurately. A shared material helps reveal differences between analytical methods and laboratory results.
This is infrastructure for science rather than a new therapy. Reliable composition supports better trials, quality control and interpretation of results. For Spain’s medicinal-cannabis discussion, the five developments contribute different things: a defined symptom-control finding, limits to common claims, an early signal, an evidence synthesis and stronger measurement.
Sources & further reading
General information, not individual legal or medical advice.